Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada

Lemtrada Stroke Lawsuit News

The list of Lemtrada alemtuzumab life-threatening side effects is growing exponentially, leading experts to question whether the benefits are worth the risks

Monday, November 9, 2020 - Lemtrada is highly effective in treating the symptoms of relapse-remitting multiple sclerosis (RRMS), but the benefits may come at a price most patients may be unwilling to pay. Reports are increasing that Lemtrada (alemtuzumab) may cause a life-threatening medical disorder called ANCA Vasculitis according to the Multiple Sclerosis Journal. "ANCA vasculitis is an autoimmune disease affecting small blood vessels in the body. It is caused by autoantibodies called ANCAs, or Anti-Neutrophilic Cytoplasmic Autoantibodies. ANCAs target and attack a certain kind of white blood cells called neutrophils," according to UNC Kidneycenter. Common symptoms of Anca Vasculitis are fever, headache, fatigue, weight loss, body aches, and nerve damage, numbness, and tingliness in the extremities. Lemtrada lawsuit lawyers offer a free consultation and no obligation to file a claim.

Anca Vasculitis News (AVN) reports that the newest known side effects are just one of many that plague patients that experiment with the drug. Others include "thyroid diseases, in which the thyroid gland produces too much or too little hormones, kidney damage, and immune thrombocytopenic purpura (caused by an immune attack against platelets)," according to AVN. Rheumatology Advisor (RA) told readers they studied the symptoms experienced by a 29-year old RRMS sufferer taking Lemtrada that had developed ANCA Vasculitis. The patient displayed "fever, auricular chondritis, cutaneous vasculitis, and life-threatening diffuse alveolar hemorrhage 12 months after initiating treatment with alemtuzumab." The patient qualified for Lemtrada which is restricted to only those with highly active RRMS in its later stages and who have tried all other drugs to try and harness their symptoms. The patient also developed bilateral conjunctivitis which led to Graves Disease 12 months after taking Lemtrada. The study included that "AASV can be added to the increasing list of alemtuzumab-induced autoimmune complications in patients [with] MS," the researchers concluded, noting that MPO-ANCA titers may prove a valuable biomarker for follow-up after alemtuzumab infusions," according to Rheumatology Advisor.

Lemtrada's life-threatening side effects have been known to the maker of the drug since inception but only recently have the public been forwarned. Lemtrada can cause a patient sudden death from stroke or heart attack either immediately or within 72 hours of treatment and that warning only was presented in 2018 when the US Food and Drug Administration (FDA) required the company to update the drug's Black Box warning label to reflect the stroke risk. Nurses that administer the drug to patients have been advised by the American Journal of nursing that, "The Food and Drug Administration has added a black box warning for alemtuzumab (Lemtrada) stating that the drug, used in the treatment of relapsing multiple sclerosis, may cause ischemic and hemorrhagic stroke and cervicocephalic arterial dissection, rare but serious adverse effects." Nurses are required to advise patients prescribed this medication to recognize and seek emergency medical care if they develop any signs or symptoms of a stroke. Lemtrada may now be administered under the watch of emergency medical personnel in a hospital with a staffed intensive care unit.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.